Sharescart Research Club logo ×
Screener Research Buy Unlisted Shares Sell Unlisted Shares Startup Funding New IPO New

Join Channel
Consolidated Standalone

Cipla

₹1499.7 16.6 | 1.1%

Market Cap ₹121132 Cr.

Stock P/E 22.9

P/B 3.9

Current Price ₹1499.7

Book Value ₹ 384.8

Face Value 2

52W High ₹1702

Dividend Yield 1.07%

52W Low ₹ 1310.1

Edit Ratio

Cipla Research see more...

Overview Inc. Year: 1935Industry: Pharmaceuticals & Drugs

Cipla Limited is an primarily India-based enterprise, usually engaged in the commercial enterprise of pharmaceuticals. The Company's segments consist of Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in growing, manufacturing, promoting and distributing widespread or branded accepted medicines, in addition to Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a customer healthcare, Biosimilars and distinctiveness enterprise. Its product portfolio spans complex generics, as well as drugs within the breathing, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, America, South Africa and Rest of the World. The Company has its community of manufacturing, buying and selling and different incidental operations in India and International markets. The Company has total of 46 manufacturing sites.

Read More..

Cipla Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Cipla Quarterly Results

#(Fig in Cr.) Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 5810 5739 6329 6678 6604 6163 6694 7051 7073 6730
Other Income 114 135 136 176 185 249 160 191 222 289
Total Income 5925 5874 6465 6854 6788 6413 6854 7242 7295 7019
Total Expenditure 4403 4566 4835 4944 4856 4847 4978 5165 5084 5192
Operating Profit 1522 1308 1630 1910 1932 1565 1876 2076 2211 1827
Interest 32 34 16 26 30 18 18 15 15 14
Depreciation 272 346 239 290 233 288 247 272 280 309
Exceptional Income / Expenses 0 -182 0 0 -195 0 0 0 0 0
Profit Before Tax 1218 745 1375 1594 1474 1259 1611 1789 1916 1504
Provision for Tax 410 222 378 438 405 325 435 483 332 279
Profit After Tax 808 523 997 1156 1069 934 1176 1306 1584 1225
Adjustments -7 3 -1 -25 -13 5 1 -3 -13 -3
Profit After Adjustments 801 526 996 1131 1056 939 1178 1303 1571 1222
Adjusted Earnings Per Share 9.9 6.5 12.3 14 13.1 11.6 14.6 16.1 19.4 15.1

Cipla Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 11345 13595 14394 15156 16362 17132 19160 21763 22753 25774 27548 27548
Other Income 166 208 229 358 477 369 270 322 512 747 862 862
Total Income 11511 13803 14623 15513 16839 17501 19429 22085 23265 26521 28409 28410
Total Expenditure 9184 11115 11919 12329 13265 13951 14911 17251 17763 19483 20420 20419
Operating Profit 2327 2688 2704 3184 3574 3550 4518 4834 5502 7038 7990 7990
Interest 168 207 159 114 168 197 161 106 110 90 62 62
Depreciation 505 754 1323 1323 1326 1175 1068 1052 1172 1051 1107 1108
Exceptional Income / Expenses 0 0 0 -78 0 0 0 -182 -182 -195 0 0
Profit Before Tax 1654 1727 1222 1669 2079 2178 3290 3493 4038 5702 6821 6820
Provision for Tax 400 332 180 250 570 631 889 934 1203 1547 1530 1529
Profit After Tax 1254 1395 1042 1419 1510 1547 2401 2559 2835 4155 5291 5291
Adjustments -73 -35 -36 -9 18 -0 4 -43 -34 -34 -19 -18
Profit After Adjustments 1181 1360 1006 1411 1528 1547 2405 2517 2802 4122 5273 5274
Adjusted Earnings Per Share 14.7 16.9 12.5 17.5 19 19.2 29.8 31.2 34.7 51.1 65.3 65.2

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 7% 8% 10% 9%
Operating Profit CAGR 14% 18% 18% 13%
PAT CAGR 27% 27% 28% 15%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -3% 17% 18% 9%
ROE Average 18% 16% 15% 13%
ROCE Average 24% 22% 20% 16%

Cipla Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 10801 11516 12544 14229 15012 15763 18327 20842 23408 26706 31193
Minority's Interest 180 350 438 352 332 294 259 276 306 96 96
Borrowings 309 222 3645 3662 3830 2369 1203 416 0 0 12
Other Non-Current Liabilities 2108 1185 868 597 816 603 457 205 184 82 -43
Total Current Liabilities 3881 7776 3374 3832 3772 4393 4591 4913 5033 5246 5484
Total Liabilities 17281 21049 20869 22673 23762 23423 24837 26652 29007 32130 36742
Fixed Assets 6830 9368 9490 9949 9547 9559 9394 9622 9101 9494 9895
Other Non-Current Assets 2860 2840 2574 1910 1789 2158 2234 2303 2631 3195 3559
Total Current Assets 7591 8841 8736 10814 12425 11704 13181 14711 16805 19392 23249
Total Assets 17281 21049 20869 22673 23762 23423 24837 26652 29007 32130 36742

Cipla Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 176 546 858 610 853 508 649 790 658 561 512
Cash Flow from Operating Activities 1173 1741 2382 1463 1691 3068 3755 3326 3238 4134 5005
Cash Flow from Investing Activities -941 -4523 -1310 -854 -1669 104 -2387 -1872 -2389 -2988 -3691
Cash Flow from Financing Activities 165 3104 -1326 -385 -349 -2949 -1240 -1600 -958 -1200 -1293
Net Cash Inflow / Outflow 397 322 -254 223 -326 224 129 -146 -109 -55 21
Closing Cash & Cash Equivalent 564 858 610 853 508 742 790 658 561 512 543

Cipla Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 14.71 16.93 12.51 17.52 18.96 19.18 29.82 31.19 34.71 51.05 65.29
CEPS(Rs) 21.91 26.76 29.4 34.06 35.2 33.76 43.02 44.76 49.65 64.49 79.22
DPS(Rs) 2 2 2 3 3 4 5 5 8.5 13 16
Book NAV/Share(Rs) 133.38 142.23 155.15 175.92 185.62 194.85 226.73 257.78 289.24 329.72 384.84
Core EBITDA Margin(%) 18.87 17.98 16.92 18.57 12.95 11.72 15.05 15.18 16.13 17.76 19.24
EBIT Margin(%) 15.91 14.02 9.44 11.72 9.4 8.76 12.22 12.11 13.41 16.35 18.58
Pre Tax Margin(%) 14.44 12.52 8.35 10.97 8.7 8.03 11.66 11.75 13.05 16.1 18.42
PAT Margin (%) 10.95 10.12 7.13 9.33 6.31 5.7 8.51 8.61 9.17 11.73 14.29
Cash Profit Margin (%) 15.36 15.59 16.17 18.02 11.86 10.03 12.29 12.15 12.95 14.7 17.27
ROA(%) 7.85 7.28 4.97 6.52 6.5 6.56 9.95 9.94 10.19 13.59 15.36
ROE(%) 12.1 12.61 8.72 10.65 10.37 10.09 14.13 13.1 12.85 16.63 18.34
ROCE(%) 15.33 13.24 8.28 10.2 11.94 12.53 17.85 17.24 18.19 22.77 23.64
Receivable days 57.94 57.62 61.36 67.94 55.36 54.1 47.44 42.19 44.13 45.49 50.64
Inventory Days 106.36 100.43 90.98 90.29 61.13 56.12 58.49 61.53 61.98 53.56 53.61
Payable days 103.91 104.98 104.58 123.84 128.32 128.84 107.95 98.28 111.52 103.64 108.56
PER(x) 48.36 30.26 47.35 31.01 27.91 22.05 27.34 32.65 25.95 29.28 22.08
Price/Book(x) 5.33 3.6 3.82 3.09 2.85 2.17 3.6 3.95 3.11 4.53 3.75
Dividend Yield(%) 0.28 0.39 0.34 0.55 0.57 0.95 0.61 0.49 0.94 0.87 1.11
EV/Net Sales(x) 5.13 3.35 3.55 3.09 2.83 2.1 3.45 3.73 3.15 4.66 4.2
EV/Core EBITDA(x) 25.03 16.92 18.91 14.72 12.97 10.12 14.63 16.77 13.02 17.06 14.48
Net Sales Growth(%) 11.52 19.83 5.88 5.29 7.96 4.7 11.84 13.59 4.55 13.28 6.88
EBIT Growth(%) -10.03 6.1 -28.55 29.11 26.01 5.69 45.26 4.31 15.23 39.63 18.84
PAT Growth(%) -11.47 11.26 -25.3 36.16 6.36 2.48 55.23 6.59 10.78 46.55 27.33
EPS Growth(%) -14.96 15.11 -26.1 40.05 8.23 1.16 55.46 4.61 11.28 47.06 27.89
Debt/Equity(x) 0.16 0.46 0.33 0.29 0.29 0.18 0.1 0.04 0.02 0.01 0
Current Ratio(x) 1.96 1.14 2.59 2.82 3.29 2.66 2.87 2.99 3.34 3.7 4.24
Quick Ratio(x) 0.99 0.65 1.56 1.77 2.24 1.67 1.85 1.91 2.31 2.7 3.21
Interest Cover(x) 10.83 9.36 8.67 15.61 13.34 12.04 21.47 33.85 37.87 64.44 111
Total Debt/Mcap(x) 0.03 0.13 0.09 0.09 0.1 0.08 0.03 0.01 0.01 0 0

Cipla Shareholding Pattern

# Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Promoter 33.41 33.41 33.4 33.4 33.4 33.4 30.86 30.86 29.13 29.13
FII 28.21 27.29 25.44 25.69 25.68 25.77 27.77 28.74 26.6 26.22
DII 20.96 21.96 24.22 24.06 24.22 24.3 24.84 24.04 27.59 28.09
Public 16.81 16.92 16.73 16.64 16.5 16.32 16.37 16.16 16.49 16.34
Others 0.61 0.42 0.2 0.21 0.21 0.21 0.16 0.21 0.2 0.22
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 27% CAGR over last 5 years
  • Company is almost debt free.

Cons

  • Promoter holding is low: 29.13%.
  • Debtor days have increased from 103.64 to 108.56days.
  • Stock is trading at 3.9 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Cipla News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!